生物活性：Erythromycin-d3 is the deuterium labeled Erythromycin[1]. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research[2][3][4][5].
IC50 & Target：Macrolide
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Erythromycin-d3 相关抗体:
Ctip2 Antibody
Rb Antibody
Phospho-Rb (Ser807) Antibody
RPA32 Antibody (YA679)
CDT1 Antibody
DNA-PKcs/PRKDC Antibody
Hes1 Antibody
JunB Antibody
LIN28A Antibody
Lin28B Antibody
MCM2 Antibody
Nanog Antibody
Nucleolin Antibody
PCNA Antibody
PDX1 Antibody
RbBP5 Antibody
S100A4 Antibody
SP1 Antibody
BRCA1 Antibody (YA819)
Argonaute 2 Antibody
BRCA1 Antibody
Elongation Factor 1A1 Antibody
KAP1 Antibody
MCM2 Antibody (YA705)
MLH1 Antibody (YA703)
RNA Polymerase II Subunit B1 Antibody
RPA70 Antibody (YA678)
MRP2 Antibody
SP7/Osterix Antibody
DNA PKcs Antibody (YA957)
分子量：736.95
Formula：C37H64D3NO13
CAS 号：959119-26-7
非标记 CAS：114-07-8
性状：固体
颜色：White to off-white
中文名称：红霉素-d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years，4°C：2 years
In solvent：-80°C：6 months，-20°C：1 month
纯度 & 产品资料
纯度： ≥95.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89.
 [Content Brief]
[3]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28.
 [Content Brief]
[4]. Hamada K, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69.
 [Content Brief]
[5]. Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67.
 [Content Brief]